Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline vs hydroxychloroquine for prevention of ovarian hyperstimulation syndrome
IRCT20240305061171N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cabergoline and hydroxychloroquine in ovarian hyperstimulation syndrome (OHSS) and polycystic ovary syndrome (PCOS) (2 arms), sponsored by Tehran University of Medical Sciences. Started Apr 2024; status: completed.
02
Drugs
cabergolinehydroxychloroquine
03
Conditions
ovarian hyperstimulation syndrome (OHSS)polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on IRCT20240305061171N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240305061171N1.